Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7Dermatologic 3Other hematologic neoplasm 2Gynecologic 2Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × denileukin diftitox × Gynecologic × Clear all
NCT01773889 2018-04-10

A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Terminated
2 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00880360 2018-03-27

ONTAK

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
19 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡